PT  - JOURNAL ARTICLE
AU  - Waasila Jassat
AU  - Cheryl Cohen
AU  - Maureen Masha
AU  - Susan Goldstein
AU  - Tendesayi Kufa
AU  - Dana Savulescu
AU  - Sibongile Walaza
AU  - Jamy-Lee Bam
AU  - Mary-Ann Davies
AU  - Hans W. Prozesky
AU  - Jonathan Naude
AU  - Ayanda T. Mnguni
AU  - Charlene A. Lawrence
AU  - Hlengani T. Mathema
AU  - DATCOV author group
AU  - Lucille Blumberg
TI  - COVID-19 in-hospital mortality in South Africa: the intersection of communicable and non-communicable chronic diseases in a high HIV prevalence setting
AID  - 10.1101/2020.12.21.20248409
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.21.20248409
4099  - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248409.short
4100  - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248409.full
AB  - Background The interaction between COVID-19, non-communicable diseases, and chronic infectious diseases such as HIV and tuberculosis (TB) are unclear, particularly in low- and middle-income countries (LMIC) in Africa. We investigated this interaction using a nationally representative hospital surveillance system in South Africa.Methods A national surveillance system for laboratory-confirmed COVID-19 hospital admissions (DATCOV) was established. Using DATCOV data, we describe the demographic characteristics, clinical features, and in-hospital mortality among individuals admitted to public and private hospitals with COVID-19 during 5 March to 11 August 2020. Multivariable logistic regression models were used to assess the role of HIV-status, underlying comorbidities and their interaction on in-hospital COVID-19-associated mortality.Findings Among the 41,877 individuals admitted with laboratory-confirmed COVID-19, hospital admissions peaked at 1,560 admissions per day, in late July and 7,662 (18.3%) died. Comorbidities were documented in 27,555 (65.8%) individuals, most commonly observed were hypertension (36.8%), diabetes (29.6%), obesity (19.7%), and HIV (8.7%); TB was reported in 0.7% of individuals. Increased risk of in-hospital mortality was associated with HIV and TB, as well as other described risk factors for COVID-19, such as increasing age, male sex, non-White race (Black, mixed and Indian race), chronic underlying conditions particularly hypertension, diabetes and obesity. In particular, HIV-infected individuals with immunosuppression had increased risk of mortality (adjusted odds ratio 2.2; 95% confidence interval 1.6-3.1). Among HIV-infected individuals, the prevalence of other comorbidities associated with severe COVID-19 outcomes was 39.9%. The effect of one or more comorbidities on mortality was similar in HIV-infected and -uninfected individuals.Interpretation These data provide a better understanding of the interaction of non-communicable diseases, chronic infectious diseases like HIV and TB and COVID-19. Increasing age and presence of chronic underlying comorbidities (particularly hypertension and diabetes) are important additional factors associated with COVID-19 mortality in a middle-income African setting and are common among HIV-infected individuals. HIV- and TB-infected individuals, particularly those with additional comorbidities, would benefit from COVID-19 prevention and treatment programmes.Funding DATCOV is funded by the National Institute for Communicable Diseases (NICD) and the South African National Government. No additional funding was obtained towards the completion of this analysis and the development of this manuscript.Research in contextEvidence before this studyEvidence before this study Since the emergence of the COVID-19 pandemic, studies from Brazil, China, India, Iran, United States and several countries in Europe have identified older age, male sex and presence of underlying comorbidities including hypertension, heart disease and diabetes as risk factors for severe disease and death. There are very few studies, however, carried out in low- and middle-income countries (LMIC) in Africa, many of whom have high poverty rates, limited access to healthcare, and high prevalence of chronic communicable diseases, such as HIV and tuberculosis (TB). Data are also limited from settings with limited access to HIV treatment programmes. Early small cohort studies mainly from high income countries were not conclusive on whether HIV or TB are risk factors for disease severity and death in COVID-19 patients. Recent large studies from South Africa’s Western Cape province and the United Kingdom (UK) have found HIV-infected individuals to have a moderately increased risk of COVID-19 associated mortality. However, the UK reported risk among all confirmed cases while data from the Western Cape suggested an increase in both all confirmed cases and those admitted to hospital. Of these, only the Western Cape study presented data on mortality risk associated with presence of high viral load or immunosuppression, and found similar levels of severity irrespective of these factors. No studies reported on the interaction between HIV-infection and other non-communicable comorbidities on COVID-19 associated mortality.We performed separate literature searches on PubMed using the following terms: “COVID-19” “death risk factors” and “mortality”; “HIV” “COVID-19” and “mortality”; “TB”, “COVID-19” and “mortality”. All searches included publications from December 2019 until July 12, 2020 without language restrictions. Pooled together, we identified 232 published papers. Additionally, we performed two literature searches on MedRxiv using the terms “HIV”, “COVID-19” and “mortality”, and “TB”, “COVID-19” and “mortality” from April 25 until July 12, 2020 without language restrictions. Pooled together, we identified six pre-prints.Added value of this studyAdded value of this study Among a large national cohort of over 40,000 individuals hospitalised with COVID-19 in a high HIV and TB prevalence setting, we found that HIV and TB were associated with a moderately increased risk of in-hospital mortality. We found increasing risk of mortality among HIV-infected individuals with moderate/severe immunosuppression compared to those without immunosuppression. Among HIV-infected individuals, the prevalence of other comorbidities was high (40%) and the effect of increasing numbers of comorbidities on mortality was similar in HIV-infected and -uninfected individuals. Our study included HIV-infected individuals from all provinces in the country with varying levels of access to HIV treatment programmes. Other risk factors described elsewhere in the world such as increasing age, obesity and chronic underlying illness (particularly hypertension and diabetes) were also associated with increased mortality in this cohort.Implications of all the available evidenceImplications of all the available evidence The evidence suggests that HIV- and TB-infected individuals should be prioritised for COVID-19 prevention and treatment programmes, particularly those with additional comorbidities. Increasing age and presence of chronic underlying illness (particularly hypertension and diabetes) are important additional factors associated with COVID-19 mortality in a middle-income African setting and are common among HIV-infected individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDATCOV is funded by the National Institute for Communicable Diseases (NICD) and the South African National Government. No additional funding was obtained towards the completion of this analysis and the development of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee (Medical), University of the Witwatersrand, approved the project protocol as part of a national surveillance program (M160667).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available through the National Institute for Communicable Diseases by permission to the corresponding author.